

2024 ACMT Symposium
Substance Use Disorder in Adolescents and Young Adults: Unique Challenges
April 11, 2024 | Washington, DC

Activity Overview

This symposium gathers experts, researchers, and healthcare professionals to explore the unique challenges surrounding adolescent substance use, including biologic differences in adolescents, psycho-social motivational differences, and medication recommendations and therapeutic interventions for this patient population. This educational event is tailored for medical toxicologists, addiction medicine specialists, pediatricians, psychiatrists, psychologists, nurses, and all healthcare providers dedicated to improving the lives of young individuals battling substance use disorders.

Target Audience

This activity is designed for an audience of physicians, pharmacists and nurses.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Developmental Vulnerabilities in Substance Use Disorders: Why Are Youth Different?

- Recognize increased risk of SU and SUD in youth.
- Identify vulnerability factor that contributes to increased risk of SU and SUD in youth.

Assessment and Treatment of SUD in Youth: Beyond SBIRT

- List the assessment domains when completing a comprehensive evaluation for SUD in youth.
- Apply the ASAM Criteria as a multidimensional assessment to recommend a level of care for youth presenting with SUD.

Opioid Use Disorder in Youth -- When To Consider MAT

- Recognize the opioid crisis in youth.
- Identify the role of MOUD in the treatment of OUD in youth.

Family Involvement in Youth SUD Treatment

- Discuss rationale and strategies to involve family members in youth OUD treatment.

Patterns and Trends

- Identify trends and patterns in youth substance use.
- Hypothesize reasons for increases in youth substance use.

Vapes & Emerging Substances

- Identify emerging substances that adolescents use or are exposed to.
- Describe concerns about adolescents using these emerging substances.

Cannabis

- Discuss the latest statistics and facts on what is really happening in legalized states.
- Understand the negative mental health outcomes of children who smoke marijuana.

Developmental Effects of Cannabis and Psychiatric Consequences

- Identify psychiatric risks of cannabis use.
- identify risks of cannabis use disorders in youth.

The Evidence for Replacing the Current Normalization of Youth Drug Use with a New Health Standard

- Describe national youth drug trends and their implications for youth prevention messaging.
- Articulate the One Choice prevention message and how it is rooted in the unique vulnerability of the developing brain to substance use.

Youth SUD Case-Based Panel

- Discuss management of SUD in youths via real case examples.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:

https://education.acmt.net/p/2024-acmt-symposium-CE#tab-product_tab_instructions

Please claim your credit by April 30, 2024.

If you have questions about this CE activity, please contact AKH Inc at JGoldman@akhcme.com.



CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 5.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 5.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 5.5 contact hours.

Nurses

Credit being awarded: 5.5 ANCC contact hours

Commercial Support

There is no commercial support for this activity.

DISCLOSURES

Name	Relationship	Commercial Interest
Camille Broussard Robinson, MD, MPH (faculty)	N/A	Nothing to disclose
Ann Bruner, MD (faculty)	N/A	Nothing to disclose
Jordan Davidson, BA (faculty)	N/A	Nothing to disclose
Robert L. DuPont, MD (faculty)	N/A	Nothing to disclose
Leslie R. Dye, MD, FACMT, FASAM, FACCT (faculty)	N/A	Nothing to disclose
Marc Fishman, MD, FASAM (faculty)	Consultant	Nirsum Labs; Drug Delivery LLC
	Researcher	Alkermes; Indivior; Braeburn
Ashley Haynes, MD, FACEP (faculty)	N/A	Nothing to disclose
Robert Cole Pueringer, MD (faculty)	N/A	Nothing to disclose
Kevin Wenzel, PhD (faculty)	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT (planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
ACMT Staff and Planners	N/A	Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.